BIOGEN INC (BIIB) Stock News
NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock - Currency: USD
BIIB Latest News, Press Relases and Analysis
Top S&P500 movers in Wednesday's session
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.
These S&P500 stocks have an unusual volume in today's session
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.
Biogen Stock Is Mutating Into a Value Play
Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
Mentions: STOK
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug
Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.
Mentions: STOK
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights ...
Biogen (BIIB) Q4 2024 Earnings Call Transcript
BIIB earnings call for the period ending December 31, 2024.
These S&P500 stocks are moving in today's session
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip
The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected.
Wednesday's session: gap up and gap down stock in the S&P500 index
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the S&P500 gap up and gap down stocks in today's session.
Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP profit of $3.44 per share was 2.3% above analysts’ consensus estimates.
Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP profit of $3.44 per share was 2.3% above analysts’ consensus estimates.
Why Investors Might Hammer Biogen Despite Its Earnings Beat
Biogen beat Q4 views Wednesday, but guided lower on 2025 profit.
Biogen Beats Estimates as Alzheimer Drug Leqembi Lifts Quarterly Sales
Biogen Inc. reported better-than-expected quarterly earnings, driven by continued growth in sales of its Alzheimer’s drug Leqembi.
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:...
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail
The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.